ArticleFrontiers in oncology2024
Triple-negative ectopic breast cancer of the male scrotum: a case report.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Ectopic breast cancer in vulva and other non-axillary sites: a systematic review.World journal of surgical oncology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Male breast cancer represents only 1% of all breast malignancies, with ectopic breast cancer in men being even rarer and highly prone to diagnostic challenges. Extramammary Paget's disease (EMPD), a rare cutaneous tumor with non-specific clinical symptoms, is susceptible to misdiagnosis. This report discusses the case of an older male patient who presented with a scrotal mass, later identified as ectopic breast invasive adenocarcinoma upon pathological examination post-lesion excision. Immunohistochemistry confirmed a triple-negative profile and EMPD diagnosis, with no malignancies detected in either breast. Despite multiple treatment regimens and recurrence following adjuvant chemotherapy, the disease progressed with associated chemotherapy-related side effects, resulting in a 25.5-month survival period. The scarcity of literature on male ectopic breast cancer complicates the understanding of its incidence and optimal treatment strategies, increasing the risk of misdiagnosis. This study highlights the diagnostic and therapeutic challenges of this rare case, emphasizing the need for early recognition of atypical manifestations. The manuscript aims to assist clinicians by sharing case-specific insights and reviewing pertinent literature to enhance comprehension and management of similarly rare cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.